Advertisement

Advertisement

HotelsFoodShoppingCoffeeGroceryGas

Meissa Vaccines Inc

+1 (650) 787-8813
Website

Advertisement

Advertisement

1100 Island Dr Ste 202
Redwood City, CA 94065
+1 (650) 787-8813
https://www.meissavaccines.com

Meissa Vaccines Inc is a biotechnology company based in Redwood City, CA, dedicated to developing live attenuated vaccines for respiratory viruses such as RSV and COVID-19. Their innovative technologies, including the proprietary AttenuBlock platform, aim to deliver effective vaccines globally, preventing infection and generating a strong immune response.

With a mission to safeguard people worldwide from life-threatening respiratory viruses, Meissa Vaccines focuses on developing safe and highly attenuated vaccine candidates that induce a better immune response than natural infection. Their RSV and COVID-19 vaccine candidates are designed to provide a durable immune response by stimulating mucosal IgA and serum neutralizing antibodies.

Generated from the website

Also at this address

Candi Controls

Glint Inc.

Trilliant

Atieva Inc

Own this business?
Claim it
See a problem?

You might also like

Avg Technologies
Business services, nec, nec, Custom computer programming services, Art gallery

Avg Technologies

Dynavax Technologies Corporation was founded in August 1996. The company discovers, develops and intends to commercialize products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, using proprietary approaches that alter immune system responses in specific ways. Its clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax s pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, which has completed a large-scale Phase 2/3 clinical trial, and is in a supportive clinical trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine that is in a pivotal Phase 3 clinical trial; a cancer therapy in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacologic activity in a Phase 2a clinical trial.
ChemoCentryx, Inc

ChemoCentryx, Inc

Founded in 1997, ChemoCentryx is a clinical-based pharmaceutical company that discovers and develops orally-administered small molecule therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It has developed EnabaLink, which is a drug recovery technology that is designed to accelerate productive drug recovery program. The company also conducts preclinical evaluation of a series of anticancer compounds that target the CXCR7 chemokine receptor. ChemoCentryx evaluates a series of compounds that target the C5a chemo-attractant receptor to treat age-related macular degeneration, rheumatoid arthritis and systemic lupus erythematosus and other disorders. It has entered into a strategic alliance with Glaxo Group, which is an affiliate of GlaxoSmithKline. ChemoCentryx maintains its headquarters in Mountain View, Calif.
Sizes, Business services, nec, nec, Feathers and feather products

Phoenix Pharmaceuticals

Founded by pioneers in the peptide industry, Phoenix Pharmaceuticals was established in 1994. The company produces more than 7,000 peptide-related products, specializing in the obesity, cardivascular and diabetes fields. See the company's website for descriptions of products and services as well as news and catalogs.
United States›California›Redwood City›Meissa Vaccines Inc

Partial Data by Infogroup (c) 2024. All rights reserved.

Advertisement

Advertisement

  • Get directions
  • MapQuest Travel
  • Route Planner
  • Print your map
  • Get help
  • Search the web
  • Send feedback
Learn more about our mobile apps.
  • Android app Google Play
  • Download on the App Store
  • Download on the Amazon Appstore
  • Enterprise solutions
  • Claim your business
  • Developer resources
  • Jobs
  • Advertise with us
  • Terms of use
  • Privacy policy
  • Data and licenses
  • About our ads
  • Do not sell